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Abstract
Background: systemic treatment of  head and neck
squamous cell carcinoma (HnsCC) includes a variety
of  antineoplastic drugs. However, drug-resistance in-
terferes with the effectiveness of  chemotherapy. Pre-
clinical testing models are needed in order to develop
approaches to overcome chemoresistance.
Methods: ten human cell lines were obtained from
HnsCC, including one with experimentally-induced
cisplatin resistance. Inhibition of  cell growth by seven
chemotherapeutic agents (cisplatin, carboplatin, 5- flu-
orouracil, methotrexate, bleomycin, vincristin, and pa-
clitaxel) was measured using metabolic Mtt-uptake
assay and correlated to clinically-achievable plasma
concentrations.
Results: all drugs inhibited cell growth in a concentra-
tion-dependent manner with an IC50 comparable to
that achievable in vivo. However, response curves for
methotrexate were unsatisfactory and for paclitaxel,
the solubilizer cremophor El was toxic. Cross-resis-
tance was observed between cisplatin and carboplatin. 
Conclusion: Chemosensitivity of  HnsCC cell lines can
be determined using the Mtt-uptake assay. for dna-
interfering cytostatics and vinca alkaloids this is a sim-
ple and reproducible procedure. determined in vitro
chemosensitivity serves as a baseline for further exper-
imental approaches aiming to modulate chemoresis-
tance in HnsCC with potential clinical signifi-
cance.
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IntRodUCtIon
In addition to surgery and radiotherapy, antineoplastic
chemotherapy is a standard treatment option for ad-
vanced head and neck squamous cell cancer (HnsCC)
[1]. Chemotherapy is currently used in adjuvant or
neoadjuvant settings combined with radiotherapy or,
in a palliative situation, as a single modality. agents
used are the platinum based substances cisplatin (CIs)
and carboplatin (CPt), 5-fluorouracil (5-fU) and tax-
anes alone or in combination [2]. But the efficacy of
chemotherapy in HnsCC remains unsatisfactory due
to the frequent development of  non-responsiveness or
chemoresistance [3]. furthermore, the frequency of
recurrent disease after chemotherapy has been unac-
ceptably high [4]. In case of  chemotherapeutically pre-
treated recurrent tumors, physicians are especially
challenged to determine an appropriate therapy.
In order to overcome drug-resistance, the explo-
ration of  underlying mechanisms is necessary. to this
end, in vitro models with cell lines established from
human HnsCC have been used, and several chemo -
therapy sensitivity and resistance assays (CsRa) are
currently available. these include: (a) the human tu-
mor cloning assay; (b) the differential staining toxicity
test, which identifies viable cells by differential dye
staining; (c) the atP-measurements after cell lysis; (d)
the extreme drug-resistance assay, which measures the
uptake of  tritiated thymidine; or (e) the Mtt-assay
based on the reduction of  dimethyl thiazolyl blue
(Mtt) to purple formazan in viable cells. But, as stat-
ed by the american society of  Clinical oncology
(asCo) in 2004, none of  the available CsRa is suit-
able for routine clinical use, because these assays either
lack an adequate prospective evaluation or they show
no improvement towards empirically given treatment.
therefore, chemosensitivity testing is only recom-
mended in a clinical trial setting [5].
the aim of  this study was to evaluate the predictive
capability of  Mtt-uptake tests towards chemosensi-
tivity in HnsCC. for this purpose, ten HnsCC cell
lines were tested for chemosensitivity against seven cy-
tostatic drugs commonly used in the clinic, namely
CIs, CPt, 5-fU, methotrexate (MtX), bleomycin
(BlM), vincristine (vCR), and paclitaxel (PtX). all
drugs were tested at the plasma concentrations achiev-
able in vivo. the obtained results can, therefore, be
easily adopted into clinical settings with potentially sig-
nificant influence on patients’ treatment.
MatERIals and MEtHods
Cell culture. for in vitro testing of  chemosensitivity,
ten established HnsCC cell lines were used. all UM-
sCC-lines (University of  Michigan squamous Cell
Carcinomas) were kindly provided by dr. t. Carey,
University of  Michigan, ann arbor, Usa. Characteri-
zation and establishment of  these cell lines were previ-
ously described [6]. Cell line Hlac 79 was obtained
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from H.P. Zenner, tuebingen, Germany. the 8029
na cell line and its CIs-resistant variant 8029 ddP
were recloned from the cell line Hlac 79 by Bier et al.
[7]. the origin of  each cell line is described in table 1.
all cell lines were cultured in dulbecco’s modified Ea-
gle’s medium (cdMEM, sigma Chemical, st. luis,
Usa) supplemented with 2mM l-gluthamine, 1%
penicillin-streptomycin, 1% non-essential amino acids
(ICn, Eschwege, Germany), and 10% fetal bovine
serum, in a humidified atmosphere of  5% Co2 at
37 °C. Mycoplasma detection tests were regularly per-
formed. viability and the number of  tumor cells were
assessed by the trypan blue dye exclusion test.
Drugs and cell treatment. antineoplastic drugs were
obtained as follows: CIs-platinex solution, CPt-carbo-
plat-50 solution and paclitaxel-taxol solution (all Bris-
tol, Munich, Germany), BlM lyophilised bleomycin-
sulfate (Mack, Illertissen, Germany), 5-fU-solution
(Rhone-Poulenc, Cologne, Germany), methotrexate
solution (lederle, Wolfratshausen, Germany), vCR so-
lution (lilly, Giessen, Germany). after one week of  in-
cubation in culture plates, tumor cells were trypsinised
into single cell suspensions. aliquots (200 µl) of  each
cell suspension were placed in wells of  96-well-plates
(falcon, lincoln Park, new Jersey, Usa). Preliminary
tests were conducted with cell numbers between 3,000
and 25,000 per well. the optimal time periods between
cell collection and drug administration as well as be-
tween the drug administration and Mtt-testing were
determined. drug concentrations which resulted in
50% inhibition of  cell growth were also determined in
preliminary tests with various drug concentrations and
are represented by the specific half  maximal inhibitory
drug concentration (IC50). Each cell line was treated
with at least five different drug concentrations, to es-
tablish the IC50 of  each cytostatic agent. Control wells
received medium alone. In order to identify potential
interference of  the lipophilic solubilizer, cell lines UM-
sCC 11B, 14C, 22B and Hlac 79 were exposed to pa-
clitaxel (PtX) + cremophor El (CEl) versus dimethyl
sulfoxide (dMso) as well as solubilizers alone.
MTT-assay. the Mtt test is based on the reduction
of  yellow tetrazolium to purple formazan by the dehy-
drogenase in cells with metabolic activity compared to
metabolically inactive cells treated with dMso [8].
tumor cells were incubated for 4h with 50µl di-
methylthiazole diphenyltetrazolium bromide per well
(Mtt 0.1%, sigma, deisenhofen). formazan was tak-
en into solution with dMso (sigma, Munich, Ger-
many) and absorption was determined at 540 nm us-
ing a photometer (Ear 400 atX, slt-labinstruments,
Crailsheim, Germany). Wells with medium, cytostatic
drug or dMso alone served as negative controls.
Graphs and statistics. for each cell line, photometric
results of  five different drug concentrations were used
for calculation of  the IC50. In the plots, the y-axis
represents cell growth, with cell growth of  the un-
treated controls representing 100%. Increasing loga-
rithmic drug concentrations are shown on the x-axis.
standard deviations of  each measurement are dis-
played by vertical bars. Results were analysed by a non-
linear parameter estimation procedure (sas-Institute
Inc., Carey, nC). Points were adjusted to sigmoid
curves (r >0.95) [9]. IC50-data were calculated as pro-
posed by Hafner et al. [10] and displayed in half  loga-
rithmic graphs (figs. 1 + 2). only the results for meto -
threxate and partly for vCR in cell lines UM-sCC
14a-C showed a biphasic course and IC50-data were
determined graphically.
REsUlts
In preliminary experiments using different tumor cell
numbers and various time periods, we established that
the dose of  6,000 tumor cells per well was the optimal
number for testing chemosensitivity, and this cell num-
ber was subsequently used in all assays. the standard
experimental protocol included tumor cell plating on
day 0, change of  medium and drug administration on
day 3 and Mtt testing on day 6.
all tested drugs inhibited cell growth of  HnsCC
cell lines in a dose-dependent manner. the IC50 values
are shown in table 2. the results were correlated to
maximum plasma concentrations of  each drug (MPC),
derived from patients undergoing antineoplastic thera-
py as previously described [11-13]. according to the
grade of  chemosensitivity, cell lines were divided into
three groups per cytostatic drug. the first group repre-
sents cell lines whose IC50 were notably under the
MPC values. all cell lines with IC50 values close to the
MPC values were included in the second group. the
third group contains cell lines with IC50 values higher
than MPC values. dose response curves were created
for each cell line. all graphs show a sigmoid curve,
with the exception of  UM-sCC 14a-C cell lines ex-
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Table 1. description and origin of HnsCC cell lines includ-
ing therapy received and survival of patients whose tumors
were established in culture.
UM-SCC 10A larynx carcinoma (t3), biopsy taken during
surgical treatment, survival time 22 months
UM-SCC 10B Biopsy of metastasis in a cervical lymph
node of the primary tumor UM-sCC 10a
UM-SCC 11B larynx carcinoma (t2n2a) after chemo -
therapy with CIs and BlM. Biopsy taken
during surgery, survival time 14 months
UM-SCC 14A Recurrent carcinoma of the mouth (t1n0)
after repeated surgical treatment and radio-
therapy. Biopsy taken during surgery, sur-
vival time 93 months
UM-SCC 14B Biopsy of second recurrence of carcinoma
UM-sCC 14a before treatment
UM-SCC 14C Biopsy of third recurrence of carcinoma
UM-sCC 14a after surgery and chemora-
diotherapy with 5-fU, vCR and MtX
UM-SCC 22B Metastasis in a cervical lymph node of a
previously untreated hypopharynx carcino-
ma (t2n1M0), survival time 10 months
HLac 79 Metastasis in a cervical lymph node of a lar-
ynx carcinoma
8029 NA Recloned subpopulation of Hlac 79 (limit-
ing dilution)
8029 DDP variant of 8029 na with experimentally in-
duced CIs resistance
EURoPEan JoURnal of MEdICal REsEaRCHaugust 20, 2010 339
Fig. 1. Growth (y-axis) of HnsCC cell lines by increasing drug concentration (x-axis). a) Representative graphs for cell lines
with low and medium IC50 compared to MPC values in humans for CIs. B) Cell lines with lower/medium and higher IC50 for
CPt and C) cell lines with low and medium IC50 compared to MPC values in humans for 5-fU.
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Fig. 2. Growth (y-axis) of HnsCC cell lines by increasing drug concentration (x-axis). a) non-sigmoid course of cell lines with
IC50 lower and higher than MPC values for MtX. B) Cell lines with lower and higher IC 50 than MPC values for BlM.
Fig. 3. IC50 values for CIs and CPt for each specific cell line. MPC values are displayed in the first column (plasma). MCP val-
ue for CIs is 1.7 – 2.5 µg/ml (left panel) and MCP value for CPt is 20 – 35 µg/ml (right panel). Cross-resistance between CIs
and CPt is displayed by increased IC50 values for both agents in cell lines UM-sCC 10a and 8029 ddP.
posed to vCR, all methotrexate measurements (fig.
2a) and UM-sCC 10a-B cell lines exposed to 5-fU.
their linear graphs lead to high variation factors for
vCR (40,000), MtX (50,000) and 5-fU (2,030). for
each drug, two representative graphs are shown in fig-
ure 1 and 2, except for PtX and vCR. 
for CIs and CPt, the IC50 values were compared
to MPC values and are separately displayed in figure
3. Cell lines UM-sCC 10a and B derive from a patient
with previously untreated larynx carcinoma. their
IC50 values for CIs lie above the MPC values and are
indicative of  a primary resistance to platinum-derived
drugs. In the cell line 8029 ddP, CIs resistance was
experimentally induced in its precursor cell line 8029
na by a gradual increase of  in vitro CIs concentra-
tions [7]. Here, the IC50 value for CIs was 2.8-fold
higher than the MPC value and 4.8-fold higher than
IC50 in the parental cell line 8029 na. at the same
time, a cross-resistance to CPt was induced, as indi-
cated by the IC50 value for CPt (5.8 µg/ml) which
was 3.9-fold higher than the MPC value (1.7-2.5
µg/ml) and 4.6-fold higher than the IC50 value for
cell line 8029 na (1.2 µg/ml). furthermore, cross-re-
sistance against BlM and methotrexate was observed:
after experimental induction of  CIs resistance in cell
line 8029 ddP, the IC50 value was 30-fold higher for
BlM and 5.5-fold higher for MtX compared to the
parental cell line 8029 na (table 2). all other cell
lines displayed IC50 values under or in range of  the
respective MPC values for CIs and CPt.
for vCR, the IC50 values for cell lines UM-sCC
14a – C were 5,000-fold higher (47-80 µg/ml) than in
other cell lines and 50-fold higher than MPC (0.37-1
µg/ml). additionally, during therapy, vCR resistance
increased from 47 µg/ml in UM-sCC 14B to 80
µg/ml in UM-sCC 14C. several other cell lines
showed a secondary increase of  cell growth in terms
of  a biphasic course under the influence of  high vCR
concentrations (data not shown). Possibly, high levels
of  vCR might induce an elongation of  the cell cycle
arrest, but so far, the nature of  this systematic inter-
fering factor remains unknown.
Cell lines UM-sCC 11B, 14C, 22B and Hlac 79
were additionally exposed to PtX combined with
CEl or dMso. for both combinations a strong dose
response was observed which correlated with the drug
concentrations ranging between 0.002 and 0.02
µg/ml. But PtX proved to be ten-fold more effective
in combination with CEl compared to dMso. More-
over, for CEl, the drug concentration for the typical
drop-off  in the dose response curve was only 100-fold
higher compared to PtX + CEl. for dMso the
drop-off  concentration was 10,000-fold higher than
for PtX + dMso. this shows that in all tested cell
lines (UM-sCC 11B, 14C, 22B, and Hlac 79) CEl in-
duced an additional cytotoxity in concentrations above
human IC50 levels. therefore, the specific cytotoxic
activity of  CEl in vitro should be considered in future
drug-resistance experiments with PtX. the present
studies were continued without PtX, as its solubilizers
CEl and dMso had an unpredictable influence on
chemosensitivity in vitro.
the chemotherapeutically pre-treated cell line UM-
sCC 11B was extremely sensitive to all tested cytostat-
ic agents and showed no drug-resistance. these find-
ings are in accordance with previous data for this cell
line, but they do not correlate with clinical experience,
as HnsCC frequently develop secondary resistance to
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Table 2. drug concentrations
which lead to a 50% inhibition of
cell growth (IC50) were deter-
mined for each cell line using six
common antineoplastic agents.
standard errors (sE) on a logarith-
mic scale are given in parentheses.
data for MtX, and partly for
vCR, were determined in the cor-
responding graph due to their
non-sigmoid curves. no sE were
calculated for MtX and partly for
vCR because of the linear re-
sponse curves. the range of IC50
values is displayed for each cyto-
static drug. the quotient of the
highest and lowest IC50 value is
displayed in the variation row.
Maximum plasma concentrations
(MPC) are based on in vivo mea-
surements performed as de-
scribed.
chemotherapy [14]. In this case, insufficient drug con-
centrations must be considered because no drug resis-
tance was determined and the survival time of  14
months was rather short.
dIsCUssIon
for dna-interfering cytostatics and vinca alkaloids
(vCR), the Mtt-assay is a simple and reproducible
procedure for determining chemosensitivity in Hn-
sCC. It has the potential to be predictive of  in vivo re-
sponses in patients undergoing chemotherapy, and the
potential value was tested in this study. the predictive
capability of  the Mtt-assay was evaluated using allo-
geneic tumor cell lines which were exposed to the cy-
totoxic drugs used at concentrations adjusted to those
usually achieved in vivo (MPC) in HnsCC patients
[11-13]. also, the origin of  the cell lines, the type of
therapy the donating patients had undergone and, in
most cases, the survival time after chemotherapy were
known. this information was valuable for the inter-
pretation of  in vitro responses of  tumor cells to the
drugs in the context of  the tumor type and the patient
clinical history. Even with only ten allogeneic HnsCC
cell lines, it was clear that their chemosensitivities to
six drugs were quite different, providing an indication
as to a potential in vivo response of  the tumor to the
MPC dose of  each drug. therefore, results of  the
Mtt-assays were informative with allogeneic cell lines
used as targets. It can be surmised that the use of  au-
tologous cell lines although demanding, would be even
more informative. Indeed, currently available methods
allow for short-term culture of  patient-specific tumor
cultures that are then tested in chemosensitivity assays
in order to help in selection of  the optimal drug and
to predict a favorable response [15]. Results of  such
chemosensitivity screens and their predictive accuracy
appear to be reasonable, although their clinical use has
not been broadly accepted so far, and efforts to estab-
lish the role of  chemosensitivity testing in predicting
longer patient survival are ongoing [16].
In this study, tumor cell growth conditions in cul-
ture and concentrations of  drugs used were estab-
lished to approximate those present in vivo. However,
comparable to most other in vitro experiments, the
Mtt-assay was performed in a fibroblast-free culture
to avoid interference by outgrowing fibroblasts [17]. It
is necessary to remember that the tumor microenvi-
ronment, including various cellular components of  tu-
mor stroma, is likely to substantially influence tumor
behavior in vitro and in vivo [18]. also, culturing tu-
mor cells as monolayers does not reproduce the true
in vivo situation. Multilayer or spheroid models and
the histoculture drug response assays (HdRa) are
three-dimensional tumor models which regularly mea-
sure higher resistance levels against cytostatic drugs
than the monolayer models [19]. the predictive capa-
bility of  the Mtt-assay would probably increase, if  it
could be implemented in such multi-dimensional mod-
els, especially those established using autologous tu-
mor cells. on the other hand, this strategy is likely to
also contribute to the assay complexity and its cost.
our results and those of  others suggest that in vitro
testing of  chemosensitivity using cultured tumor cells
has a clinical utility. additionally, the emergence of
new anti-neoplastic agents in oncology calls for fur-
ther development of  assays which are able to reliably
predict tumor chemoresistance. for these reasons, the
application of  Mtt-based assays to clinical decision
making and their improved predictive significance in
estimates of  chemosensitivity are becoming an impor-
tant component of  oncologic practice.
among the cytostatics with widespread use in can-
cer treatment are platinum-based agents, CIs and
CPt, and resistance of  tumor cells to these drugs is of
great interest. the best known mechanisms of  plat-
inum-based drug resistance include: (a) up-regulation
of  copper efflux transporters in the tumor cell mem-
brane [20]; (b) reduced absorption of  CIs; (c) up-reg-
ulated intracellular dna repair systems [21]; and (d)
increased intracellular gluthatione [22]. furthermore,
the influence of  p53 mutations on CIs sensitivity has
been suggested [23], and distinct changes in gene ex-
pression, e.g. c-met, have been described in CIs resis-
tant tumor cell lines [24]. these resistance mecha-
nisms may apply to the cell line 8029 ddP used in
our experiments. Cross-resistance to BlM was ob-
served in this CIs-resistant cell line, which displayed
an increased IC50 value for BlM after experimental
induction of  CIs resistance. so far, no connection be-
tween BlM and CIs resistance has been described,
but the phenomenon of  multidrug-resistance based
on the involvement of  multiple membranous trans-
port proteins could be a relevant mechanism [14].
When comparing the chemosensitivity results for the
two platinum-based agents (CIs and CPt) in HnsCC
cell lines, similar antineoplastic activity was observed
suggesting that the cause of  cross-resistance lies in
the structural and functional analogy of  the platin-
based cytostatics. However, to obtain an equivalent
antineoplastic activity, a 16-fold higher concentration
of  CPt than CIs was necessary, as also reported by
others [25]. the relatively low activity of  CPt is be-
lieved to depend on its decreased ability to form in-
trastrand crosslinks [26]. the issue of  CIs resistance
is of  especially high clinical interest in head and neck
oncology and may be approached systematically by
using the current in vitro model. the present work of-
fers a baseline for further identification of  drug-resis-
tance mechanisms in HnsCC by providing detailed
chemosensitivity data obtained in several tumor cell
lines.
due to its high response rate combined with low
toxicity, MtX is a favourable cytostatic drug in pallia-
tive treatment of  HnsCC. However, our data show
poor response level for MtX with several cell lines
displaying an IC50 value which was only just below or
above MPC values. after tumor biopsy to establish
the cell line UM-sCC 14B, the patient was treated
with surgery as well as MtX, 5-fU and vCR in a 
multi-drug regimen. UM-sCC 14C was taken from 
recurrent disease, which presumably acquired an in-
creased resistance against these drugs. In our panel 
of  cell lines, MtX resistance was 100-fold higher 
in UM-sCC 14C compared to the precursor cell 
lines UM-sCC 14a and B. so, despite the poor re-
sponse levels for MtX, secondary drug resistance was
recognized correctly by Mtt-uptake. However, 
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the plateau in the graph for MtX resistance might
have resulted in significant but not necessarily biologi-
cally important statistical differences in the IC50 
values.
In the same cell lines, UM-sCC 14a-C, it was
shown that the tumor possessed a primary resistance
to vCR, as IC50 levels of  these tumor samples were
manifold increased. still, vCR resistance increased
during therapy. therefore, it is reasonable that treat-
ment with vCR in this patient had the same effect as
low-dose chemotherapy which leads to an increase of
drug resistance. similar conditions can develop in non-
resistant tumors in vivo, where various factors like su-
perinfection, variation of  blood supply and hetero-
geneity of  the tumor (e.g. central necrosis, fibrosis)
lead to inconsistent drug concentrations in situ. In this
way, solid tumors create ideal conditions for the devel-
opment of  drug-resistance by low cytostatic drug con-
centrations [27].
also in the same cell lines, UM-sCC 14B and C, no
change was seen in 5-fU resistance, despite the fact,
that the multidrug treatment included 5-fU. this
could be due to an insufficient drug concentration or
the lack of  predictive capability in the experimental
setting for 5-fU. summarizing the results for cell lines
UM-sCC 14a-C, the Mtt-assay correctly recapitulat-
ed results for MtX and vCR, but those for 5-fU re-
main questionable. the non-sigmoid response curve
for 5-fU in some of  the cell lines (UM-sCC 10a and
B), which lead to an increased variation factor, might
be of  experimental origin. Coley et al observed a cell
swelling caused by an increase of  intracellular mito-
chondria and consequently a simulation of  higher ab-
sorbance levels under 5-fU in the Mtt assays [28].
the same phenomenon was described using genistein,
an unspecific tyrosine kinase inhibitor [29]. therefore,
obtained results for 5-fU must be viewed carefully,
even though in other studies no interference with 5-
fU was described.
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